The Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (Xolair®) technology appraisal recommends this treatment as an option for treating severe persistent confirmed allergic IgE‑mediated asthma in individuals who need continuous or frequent treatment with oral corticosteroids. This recommendation is made provided the treatment is made available with the discount agreed in the patient access scheme.
The Gout - canakinumab (Ilaris®) technology appraisal was terminated because no evidence submission was received from the manufacturer. As such the treatment cannot be recommended.
The Idiopathic pulmonary fibrosis - pirfenidone (Esbriet®) technology appraisal is recommended for patients with a predicted FVC between 50% and 80% and provided the treatment is made available with the discount agreed in the patient access scheme. Treatment should be stopped if the predicted FVC decline by more than 10% in 12 months.
The Rheumatoid arthritis - abatacept (2nd line) (Orencia®) technology appraisal recommends this treatment in combination with methotrexate as an option for treating rheumatoid arthritis in adults whose disease has responded inadequately to two conventional DMARDs. This recommendation is based upon it being used in accordance with the recommendations for other biological DMARDs as defined in TA130 and provided the treatment is made available with the discount agreed in the patient access scheme.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.